Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

In addition, Dupixent is approved to treat the following: corticosteroid-dependent asthma in children ages 6 years and older CRwNP in children ages 12 years and older atopic dermatitis (eczema ...

By targeting the IL-4 beta receptor and IL-13, the researchers said, dupilumab (Dupixent; Sanofi, Regeneron) manages atopic dermatitis and improves depression and anxiety, but evidence about its ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

The redness, discoloration, dryness, and itch of atopic dermatitis (AD) could send you to your dermatologist in search of solutions. Your doctor will start by taking stock of your symptoms.

Apogee plans a 2025 Phase 1b trial comparing APG279 to Dupixent in atopic dermatitis. Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who ...

The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic dermatitis ... versus Sanofi and Regeneron’s Dupixent remain unanswered.

Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...